Biostage Correlations
| BSTGDelisted Stock | USD 4.20 0.09 2.10% |
The current 90-days correlation between Biostage and Covalon Technologies is 0.04 (i.e., Significant diversification). The correlation of Biostage is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Biostage Correlation With Market
Modest diversification
The correlation between Biostage and DJI is 0.21 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Biostage and DJI in the same portfolio, assuming nothing else is changed.
Biostage |
The ability to find closely correlated positions to Biostage could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biostage when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biostage - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biostage to buy it.
Moving together with Biostage OTC Stock
| 0.77 | SHG | Shinhan Financial | PairCorr |
| 0.9 | EC | Ecopetrol SA ADR | PairCorr |
| 0.79 | HYMTF | Hyundai Motor | PairCorr |
| 0.83 | TLK | Telkom Indonesia Tbk | PairCorr |
| 0.7 | BA | Boeing Fiscal Year End 29th of January 2025 | PairCorr |
| 0.93 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.72 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Biostage OTC Stock
| 0.91 | CSCO | Cisco Systems Aggressive Push | PairCorr |
| 0.86 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
| 0.79 | BAC | Bank of America Fiscal Year End 10th of January 2025 | PairCorr |
| 0.79 | WMT | Walmart Aggressive Push | PairCorr |
| 0.79 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
| 0.78 | CVX | Chevron Corp Fiscal Year End 7th of February 2025 | PairCorr |
| 0.77 | HPQ | HP Inc | PairCorr |
| 0.75 | TRV | The Travelers Companies Fiscal Year End 17th of January 2025 | PairCorr |
| 0.72 | JPM | JPMorgan Chase Fiscal Year End 10th of January 2025 | PairCorr |
| 0.72 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.63 | KB | KB Financial Group | PairCorr |
| 0.61 | XOM | Exxon Mobil Corp Sell-off Trend | PairCorr |
| 0.43 | VFS | VinFast Auto Earnings Call Tomorrow | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Biostage OTC Stock performing well and Biostage OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Biostage's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BITRF | 3.09 | (1.18) | 0.00 | (0.51) | 0.00 | 1.34 | 62.53 | |||
| BIOAF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| CVALF | 1.92 | 0.22 | 0.06 | 0.59 | 2.00 | 6.67 | 11.79 | |||
| CPMV | 6.66 | 0.91 | 0.04 | (2.85) | 9.11 | 25.71 | 81.86 | |||
| CRPOF | 123.42 | 59.90 | 8.56 | 3.04 | 0.00 | 10.53 | 4,159 | |||
| CMVLF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| SNBIF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| PRNAF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| INNMF | 9.47 | 0.86 | 0.03 | (1.50) | 11.72 | 25.00 | 120.02 | |||
| ADYX | 6.52 | 0.63 | 0.00 | 0.29 | 0.00 | 0.00 | 266.67 |
View Biostage Related Equities
| Risk & Return | Correlation |
Biostage Corporate Management
Elected by the shareholders, the Biostage's board of directors comprises two types of representatives: Biostage inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biostage. The board's role is to monitor Biostage's management team and ensure that shareholders' interests are well served. Biostage's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biostage's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yu Hong | President | Profile | |
| Joseph Damasio | Chief Officer | Profile | |
| Shunfu Hu | VP Operations | Profile | |
| William Fodor | Chief Officer | Profile |
Still Interested in Biostage?
Investing in delisted otcs can be risky, as the otc stock is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.